BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 14726986)

  • 1. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.
    LLerena A; Dorado P; Berecz R; González AP; Peñas-LLedó EM
    Eur J Clin Pharmacol; 2004 Feb; 59(12):869-73. PubMed ID: 14726986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.
    Scordo MG; Spina E; Dahl ML; Gatti G; Perucca E
    Basic Clin Pharmacol Toxicol; 2005 Nov; 97(5):296-301. PubMed ID: 16236141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders.
    Sagahón-Azúa J; Medellín-Garibay SE; Chávez-Castillo CE; González-Salinas CG; Milán-Segovia RDC; Romano-Moreno S
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00864. PubMed ID: 34523245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine.
    Ring BJ; Eckstein JA; Gillespie JS; Binkley SN; VandenBranden M; Wrighton SA
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1044-50. PubMed ID: 11356927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients.
    Gassó P; Rodríguez N; Mas S; Pagerols M; Blázquez A; Plana MT; Torra M; Lázaro L; Lafuente A
    Pharmacogenomics J; 2014 Oct; 14(5):457-62. PubMed ID: 24663076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.
    Berecz R; de la Rubia A; Dorado P; Fernández-Salguero P; Dahl ML; LLerena A
    Eur J Clin Pharmacol; 2003 May; 59(1):45-50. PubMed ID: 12682803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients.
    LLerena A; Dorado P; Berecz R; González A; Jesús Norberto M; de la Rubia A; Cáceres M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jan; 783(1):25-31. PubMed ID: 12450521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations.
    Llerena A; Berecz R; Dorado P; de la Rubia A
    J Psychopharmacol; 2004 Jun; 18(2):189-93. PubMed ID: 15260906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing the effect of cytochrome P450 (CYP) 2C8, CYP2C9, and CYP2D6 genetic polymorphisms on stereoselective N-demethylation of fluoxetine.
    Wang Z; Wang S; Huang M; Hu H; Yu L; Zeng S
    Chirality; 2014 Mar; 26(3):166-73. PubMed ID: 24464553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.
    LLerena A; de la Rubia A; Berecz R; Dorado P
    Pharmacopsychiatry; 2004 Mar; 37(2):69-73. PubMed ID: 15048614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
    Jin Y; Desta Z; Stearns V; Ward B; Ho H; Lee KH; Skaar T; Storniolo AM; Li L; Araba A; Blanchard R; Nguyen A; Ullmer L; Hayden J; Lemler S; Weinshilboum RM; Rae JM; Hayes DF; Flockhart DA
    J Natl Cancer Inst; 2005 Jan; 97(1):30-9. PubMed ID: 15632378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes.
    Liu ZQ; Shu Y; Huang SL; Wang LS; He N; Zhou HH
    Acta Pharmacol Sin; 2001 Jan; 22(1):85-90. PubMed ID: 11730569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concentrations of Fluoxetine Enantiomers Decline During Pregnancy and Increase After Birth.
    Wisner KL; Avram MJ; George AL; Abramova TV; Yang A; Caritis SN; Costantine MM; Stika CS
    J Clin Psychopharmacol; 2024 Mar-Apr 01; 44(2):100-106. PubMed ID: 38421920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors.
    Nelson MH; Birnbaum AK; Remmel RP
    Epilepsy Res; 2001 Apr; 44(1):71-82. PubMed ID: 11255075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE; Ahern D; Scatina J; Kao J
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
    Ereshefsky L; Riesenman C; Lam YW
    Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.
    Lam YW; Gaedigk A; Ereshefsky L; Alfaro CL; Simpson J
    Pharmacotherapy; 2002 Aug; 22(8):1001-6. PubMed ID: 12173784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.
    Coller JK; Krebsfaenger N; Klein K; Endrizzi K; Wolbold R; Lang T; Nüssler A; Neuhaus P; Zanger UM; Eichelbaum M; Mürdter TE
    Br J Clin Pharmacol; 2002 Aug; 54(2):157-67. PubMed ID: 12207635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.
    Kirchheiner J; Meineke I; Müller G; Bauer S; Rohde W; Meisel C; Roots I; Brockmöller J
    Clin Pharmacokinet; 2004; 43(4):267-78. PubMed ID: 15005635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine.
    Fjordside L; Jeppesen U; Eap CB; Powell K; Baumann P; Brøsen K
    Pharmacogenetics; 1999 Feb; 9(1):55-60. PubMed ID: 10208643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.